생식 보조 의료 기술(ART)에 대한 인식과 이용 증가는 유전자 이상이나 불임의 우려 증가와 함께 착상전 유전학적 검사 시장을 촉진하고 있습니다. 연구의 애널리스트에 따르면 착상전 유전학적 검사 시장은 2023년의 평가액 6억 2,191만 달러 미만으로, 2031년에는 13억 3,409만 달러의 평가액에 달할 것으로 추정됩니다.
차세대 시퀀싱(NGS) 및 어레이 비교 유전체 하이브리드화(aCGH)와 같은 유전체 기술의 진보는 보다 정확하고 종합적인 유전자 스크리닝을 가능하게 하고 시장 성장을 가속화합니다. 착상전 유전학적 시장은 2024년부터 2031년까지 연평균 복합 성장률(CAGR) 10.01%로 성장할 전망입니다.
착상전 유전학적 검사 시장 정의/개요
착상전 유전학적 검사는 체외수정(IVF)에 의해 만들어진 배아에 대한 전문적인 유전자 검사 과정입니다 자궁에 넣기 전에 각 배아에서 하나 또는 몇 개의 세포를 생검하고 유전적 구성을 결정합니다. 착상전 유전학적 검사는 주로 배아의 유전자 이상, 염색체 이상 또는 특정 유전자 변이를 발견하는 데 사용됩니다.
게다가, 이 방법은 유전성 질환을 이어받을 위험이 있는 부부, 반복성 유산 및 체외수정(IVF) 실패의 병력이 있는 사람, 불임 치료를 원하는 노인 여성에게 특히 유용합니다. 성질환이 없는 배아를 선택할 수 있게 하고, 임신의 성공과 건강한 아이의 탄생 가능성을 높입니다.
유전자 검사는 수정란의 초기 단계에서 유전자의 이상이나 질병을 발견하는 이점이 이해되고 일반인들 사이에서 인기를 모으고 있습니다. 어머니의 나이가 높은 부부 또는 여러 번 임신에 실패한 경험이 있는 부부 사이에서 건강한 아기를 바라는 경향이 높아지고 있는 것에 수반하고 있습니다. 착상전 유전학적 검사를 확립하는 중요한 추진력이 되고 있습니다.
착상전 유전학적 검사 시장은 차세대 시퀀싱(NGS), 중합효소 연쇄반응(PCR), 마이크로어레이법 등의 유전자 검사 기술의 진보로부터 큰 이익을 얻고 있습니다. 검사의 정도, 효율, 속도를 향상시켜 착상전 유전학적 검사를 보다 가까이에서 신뢰할 수 있게 했습니다.
게다가, 세계의 유전성 질환 유병률은 진단 방법의 개선이나 인지도도 증가하고 있습니다. 유산, 사산을 경험한 부부는 아이에게 유전적 이상이 옮겨질 가능성을 낮추기 위해 착상전 유전학적 검사를 선택할 가능성이 높아지고 있습니다.
착상전 유전학적 검사는 체외수정(IVF)에 의한 임신 전에 배아에 유전적 문제가 있는지 여부를 평가하는 과정입니다. 이것은 유전적 특징에 따라 배아를 선택하는 것에 대한 윤리적 우려를 제기하고 "디자이너 아기"로 이어질 수 있습니다. 주요 유전 질환을 피하기 위해 착상전 유전학적 검사를 이용하는 것과 바람직한 특징을 선택하는 사이에는 좁은 경계가 있으며, 우생학, 불공정, 편견에 관한 사회적, 도덕적, 윤리적 우려가 생겨 시장 성장이 제한됩니다.
착상전 유전학적 검사 기술은 비약적인 진보를 이루었지만, 정밀도, 효율성, 폭넓은 유전성 질환을 검출하는 능력이라는 점에서는 여전히 한계가 있습니다. 위양성과 위음성이 발생하여 생존 가능한 배아가 파괴되거나 진단되지 않은 유전자 이상을 가진 배아가 선별됩니다. 착상전 유전학적 검사의 정확성과 범위를 향상시키기 위해서는 지속적인 R&D가 필요하며 비용과 시간이 많이 소요되므로 시장 확대에는 한계가 있습니다.
The growing awareness and use of assisted reproductive technologies (ART), along with increased occurrences of genetic abnormalities and infertility concerns, is propelling the preimplantation genetic testing (PGT) market. According to the analyst from Verified Market Research, the Preimplantation Genetic Testing Market is estimated to reach a valuation of USD 1334.09 Million in 2031 over the forecast subjugating around USD 621.91 Million valued in 2023.
Advancements in genomic technologies, such as next-generation sequencing (NGS) and array comparative genomic hybridization (aCGH), are allowing for more precise and comprehensive genetic screening, accelerating market growth. It enables the market to grow at a CAGR of 10.01% from 2024 to 2031.
Preimplantation Genetic Testing Market: Definition/Overview
Preimplantation Genetic Testing (PGT) is a specialized genetic testing process for embryos generated through in vitro fertilization (IVF). Before being put into the uterus, one or a few cells from each embryo are biopsied to determine their genetic makeup. PGT is primarily used to discover genetic abnormalities, chromosomal problems, or specific genetic mutations in embryos, allowing prospective parents to make educated decisions about embryo selection for implantation.
Furthermore, this method is especially useful for couples at risk of passing on genetic illnesses, individuals with a history of recurrent pregnancy loss or unsuccessful IVF attempts, and older women seeking fertility treatments. PGT allows for the selection of embryos free of genetic diseases, boosting the chances of a successful pregnancy and the birth of a healthy child.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Genetic testing is gaining popularity among the general public, owing to a better understanding of its benefits in detecting genetic abnormalities and ailments early in the embryonic stage. This awareness is accompanied by a rising preference for healthy babies, particularly among couples with a history of genetic diseases, those of advanced maternal age, or those who have experienced several pregnancy losses. This desire to protect future generations' health and well-being is an important driver to establishing preimplantation genetic testing (PGT).
The Preimplantation Genetic Testing Market has profited greatly from advances in genetic testing technologies such as Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Microarray methods. These technologies have increased the accuracy, efficiency, and speed of genetic testing, making PGT more accessible and dependable. Furthermore, advances in IVF equipment and procedures support these genetic testing improvements, making it easier to incorporate PGT into fertility treatments.
Furthermore, the global prevalence of genetic illnesses is increasing, owing in part to improved diagnosis procedures and more awareness. Couples with known genetic problems in their families, as well as those who have had unexplained infertility, miscarriages, or stillbirths, are more likely to choose PGT to lower the possibility of transferring genetic abnormalities to their children. This generational trend broadens the potential consumer base for PGT services, resulting in market growth.
Preimplantation genetic testing (PGT) is the process of evaluating embryos for genetic problems before to pregnancy using in vitro fertilization. This raises ethical concerns about selecting embryos based on genetic features, which might lead to "designer babies." There is a narrow line between utilizing PGT to avoid major genetic illnesses and choosing desirable features, which creates social, moral, and ethical concerns about eugenics, injustice, and prejudice, thereby limiting market growth.
While PGT technologies have made tremendous advances, they still have limits in terms of accuracy, efficiency, and capacity to detect a wide spectrum of genetic disorders. False positives or negatives occur, resulting in the destruction of viable embryos or the selection of embryos with undiagnosed genetic abnormalities. Improving the accuracy and scope of PGT necessitates continual research and development, which is expensive and time-consuming, limiting market expansion.
According to VMR analyst, the reagents and consumables segment is anticipated to dominate the segment within the Preimplantation Genetic Testing Market. Reagents and consumables are required at all stages of the PGT process, from DNA amplification to analysis. These items are used in big quantities and require regular replenishment, resulting in a steady demand. Unlike instruments, which are long-term capital investments, reagents and consumables are continuing operating expenses for genetic testing laboratories. This large volume utilization greatly increases their market share.
The field of genetic testing, including PGT, is quickly growing, with ongoing advances and breakthroughs in reagents and consumables. These advancements have the potential to improve the accuracy, speed, and efficiency of testing processes. Also, the flexibility to tailor reagents and consumables to specific tests or conditions helps accelerate their adoption, addressing the precise requirements of PGT laboratories and clinics.
Furthermore, reagents and consumables are used in a variety of PGT procedures, including Preimplantation Genetic Screening (PGS) for aneuploidy detection, Preimplantation Genetic Diagnosis (PGD) for single gene diseases, and newer approaches for structural rearrangements and mitochondrial illnesses. These products' market domination is due to their adaptability and requirement in a variety of PGT applications.
The preimplantation genetic diagnosis (PGD) segment is estimated to hold the largest share of the Preimplantation Genetic Testing Market during the forecast period. PGD is utilized specifically by couples who are known to have a high chance of passing on specific genetic disorders to their children. This specialized approach to testing detects single-gene disorders and chromosomal anomalies unique to the parents' genetic origins, making it an essential tool for families looking to avoid the transfer of hereditary diseases. The need for PGD stems from its capacity to bring peace of mind to at-risk couples by ensuring the birth of healthy offspring free of specific genetic abnormalities.
Furthermore, the general public and healthcare professionals are becoming increasingly aware of the benefits of genetic testing in preventing inherited disorders. This awareness, combined with the rising occurrence of genetic abnormalities due to a variety of reasons, including longer parental ages at conception, has resulted in increased demand for PGD. Prospective parents are becoming more knowledgeable and proactive about their reproductive options, resulting in an increase in the use of PGD to assure the health and well-being of their future offspring.
According to VMR analysis, the North American region is estimated to dominate in Preimplantation Genetic Testing Market during the forecast period. Genetic testing and its benefits are widely understood and accepted in North America. This is due in part to healthcare providers' educational efforts, patient group activism, and media and popular culture coverage. As a result, there is a high demand for genetic testing services, including PGT, among people and couples seeking to uncover genetic abnormalities, assess risks to future children, and make educated reproductive decisions. This desire is amplified by the cultural acceptance of IVF and related reproductive technologies.
Furthermore, North America, particularly the United States, has some of the world's most advanced healthcare infrastructure, with cutting-edge medical facilities, leading-edge research institutions, and a strong emphasis on new healthcare solutions. This infrastructure facilitates considerable research and development efforts in genetic testing and reproductive technologies. Furthermore, substantial healthcare expenditure in the region, both public and private, allows for significant investment in new technology and treatments, making modern PGT services broadly available to patients.
Asia Pacific is estimated to grow at the highest CAGR in the Preimplantation Genetic Testing Market. This region has experienced substantial growth in awareness and acceptance of genetic testing and its potential advantages. This is attributable to improved knowledge, more access to information via digital platforms, and government-led initiatives to promote genetic health. As a result, more people and couples are using PGT as part of their family planning, increasing market demand.
Furthermore, governments around Asia Pacific are making significant investments in healthcare infrastructure as well as encouraging biotechnology and genetic engineering research. Countries such as China, Japan, South Korea, and Singapore are setting the standard for enacting policies that encourage the adoption of modern medical technology, including PGT. These measures, combined with supporting legislative frameworks, are considerably boosting the region's PGT market.
The competitive landscape of the preimplantation genetic testing (PGT) market is marked by a constant interplay of technology breakthroughs, regulatory frameworks, and shifting customer preferences. Furthermore, cooperation among healthcare providers, research institutions, and technology companies are pushing innovation and broadening the use of PGT beyond typical genetic disorders to include broader genomic profiling.
Some of the prominent players operating in the Preimplantation Genetic Testing Market include:
Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., PerkinElmer Inc., CooperSurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Genea Limited, Progenesis, Igenomix.
In April 2023, Eurofins Genoma, a leader in the PGT market, launched niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. This new test analyses cell-free foetal DNA in the maternal bloodstream, providing a less intrusive option for couples undergoing in vitro fertilization (IVF).
In April 2023, LifeView, powered by Genomic Prediction, announced a partnership with Ovation Fertility. This agreement gives Ovation patients access to the LifeView PGT Platform, which provides cutting-edge technology and might significantly improve their clinical care experience.